(Q34156097)

English

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

follicular lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Pierre-Louis Soubeyran

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

René-Olivier Casasnovas

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1

object named as

Gilles Salles

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

6

object named as

Luc Xerri

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

7

object named as

Pierre Feugier

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

10

object named as

Pauline Brice

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

14

object named as

Alain Delmer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Christophe Fermé

21

object named as

Christophe Fermé

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Catherine Sebban

23

object named as

Catherine Sebban

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

27

object named as

Anne Sonet

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

30

object named as

Hervé Tilly

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Bertrand Coiffier

29

object named as

Bertrand Coiffier

1 reference

Europe PubMed Central

PubMed publication ID

18 January 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

John Vincent Catalano

9

object named as

John Vincent Catalano

1 reference

Europe PubMed Central

PubMed publication ID

18 January 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

25

object named as

Jane A Estell

1 reference

Europe PubMed Central

PubMed publication ID

18 January 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

author name string

John Francis Seymour

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Fritz Offner

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Armando López-Guillermo

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Réda Bouabdallah

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Dolores Caballero

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Lars Moller Pedersen

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Anton Hagenbeek

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Tanin Intragumtornchai

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Andrew Lister

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Gustavo Milone

26

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Myriam Mendila

28

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Maria Gomes da Silva

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

language of work or name

0 references

publication date

20 December 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

377

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

9759

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

42-51

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Improved survival of follicular lymphoma patients in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Ongoing Improvement in Outcomes for Patients Diagnosed as Having Non-Hodgkin Lymphoma From the 1990s to the Early 21st Century

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Follicular lymphoma: prognostic factors for response and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory foll

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Follicular lymphoma international prognostic index.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

From the bench to the bedside: ways to improve rituximab efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Transformation of follicular lymphoma to diffuse large B-cell lymphoma may occur by divergent evolution from a common progenitor cell or by direct evolution from the follicular lymphoma clone.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

S(mu) mutation patterns suggest different progression pathways in follicular lymphoma: early direct or late from FL progenitor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2962175-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(10)62175-7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176949%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34156097&oldid=2120335841"